Condition: Urinary Bladder, Overactive · Incontinence, Urge · Incontinence, Urinary · Sponsor: University of South Florida
Currently, in clinical practice there has been no standardization in the number of injections a single dose of intradetrusor onabotulinumtoxin A is administered in. Given the increasing use of this treatment modality, the aim of this study is to compare outcomes for patients given a 100 unit dose of onabotulinumtoxin A split into 5 as compared to 20 injections for the treatment of overactive bladder or urgency urinary incontinence refractory to medical treatment.
This description comes directly from the study's public registry record.
Eric S Chang, MD · 813-259-8500 · ericchang@usf.edu
Allison Wyman, MD · 813-259-8500 · awyman@usf.edu
Always discuss trial participation with your own doctor first.
| MedStar Washington Hospital Center | Washington D.C., District of Columbia, United States | Recruiting |
| University of South Florida Health South Tampa Center for Advanced Healthcare | Tampa, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04305743